This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D70 | Synonyms: Kostmann syndrome, Severe congenital neutropenia type 1 (SCN1), infantile agranulocytosis (hereditary)
Congenital agranulocytosis was first described in 1956 when the Swedish pediatrician Rolf Kostmann reported pediatric patients from a large family in an isolated village in northern Sweden who showed severe recurrent bacterial infections beginning within the first few months of life and near-complete loss of blood neutrophils. Kostmann proposed that the disease was inherited in an autosomal recessive manner and described the characteristic finding of arrested maturation in the bone marrow beyond the myelocyte stage.
The original family described by Kostmann was followed for decades thereafter, and in 2003–2007 Carlsson and colleagues analyzed the genotype of this original family and identified mutations in the HAX1 gene (HCLS1-associated protein X-1) as the cause. Interestingly, the HAX1 mutation was found in the very family originally described by Kostmann, and it is now established that the molecular cause of 'Kostmann syndrome' is HAX1 mutation.
Since the 1990s, molecular genetic research has revealed that severe congenital neutropenia can be caused by mutations in various genes, including ELA2 (ELANE), HAX1, G6PC3, GFI1, VPS45. In the early 2000s, as Welte and colleagues accumulated large cohort data through the international Severe Chronic Neutropenia International Registry (SCNIR), the natural history of the disease and the risk of leukemic transformation were systematically studied.
In 1989, Welte, Souza and colleagues reported that granulocyte colony-stimulating factor (G-CSF, filgrastim) markedly increased neutrophil counts in patients with severe congenital neutropenia. The introduction of G-CSF treatment dramatically improved the prognosis of patients with this disease, but concerns were also raised that long-term G-CSF use might increase the risk of leukemic transformation.
Congenital agranulocytosis (including Kostmann syndrome) is caused by mutations in the following genes.
| Gene | Location | Mode of inheritance | Features |
|---|---|---|---|
| ELANE(ELA2) | 19p13.3 | AD (rarely AR) | Most common cause of SCN (~60%), neutrophil elastase |
| HAX1 | 1q21.3 | AR | Kostmann's original family; neurological abnormalities in some |
| G6PC3 | 17q21.31 | AR | Possible cardiac malformations, microtia, genitourinary abnormalities (SCN4) |
| GFI1 | 1p22.1 | AR/AD | SCN type 2 |
| VPS45 | 1q21.2 | AR | Accompanied by bone marrow failure, reduced renal function |
| SRP54 | 14q13.2 | AD | Relatively recently discovered, moderate SCN |
The inheritance pattern of congenital agranulocytosis varies with the causative gene. ELANE mutations: autosomal dominant (SCN1, OMIM#202700). HAX1 mutations: autosomal recessive (Kostmann syndrome, OMIM#610738). G6PC3 mutations: autosomal recessive (SCN4, OMIM#612541).
The ELANE gene encodes the elastase of neutrophil primary granules. Mutations cause protein misfolding, leading to endoplasmic reticulum stress and promoting apoptosis of myeloid progenitor cells. ELANE mutations can cause both cyclic neutropenia (about 21-day cycle) and severe congenital neutropenia.
Of the two HAX1 isoforms (A, B), mutations affecting isoform B are accompanied by neurological abnormalities (epilepsy, learning disabilities). HAX1 is involved in maintaining mitochondrial membrane potential and inhibiting apoptosis.
When acquired point mutations in the CSF3R gene (especially truncation mutations) arise during G-CSF treatment, the risk of transformation to leukemia (mainly AML) increases. This is understood as the result of G-CSF-dependent clonal selection pressure.
The prevalence of severe congenital neutropenia (including Kostmann syndrome) is estimated at about 1–2/1,000,000. Data on more than 600 patients have been registered to date in the Severe Chronic Neutropenia International Registry (SCNIR).
SCN due to ELANE mutations occurs worldwide without ethnic bias. Kostmann syndrome due to HAX1 mutations is reported relatively more often in populations where consanguineous marriage is common, particularly in the Middle East, Turkey, and Iran.
In Korea, congenital agranulocytosis is classified as an ultra-rare disease. Sporadic cases have been reported in domestic pediatric hematology-oncology, including reported cases of ELANE and HAX1 mutations. Accurate domestic prevalence statistics are lacking, but it is included in the rare disease registry database.
The core pathophysiology of congenital agranulocytosis is arrest of neutrophil maturation in the bone marrow at the myelocyte or promyelocyte stage. As a result, neutrophils are almost completely absent from the peripheral blood (ANC <200/μL).
ELANE mutations cause misfolding of the neutrophil elastase protein. When misfolded protein accumulates in the endoplasmic reticulum, the unfolded protein response (UPR) is activated. Persistent UPR promotes apoptosis of promyelocyte and myelocyte progenitor cells, blocking the production of mature neutrophils.
HAX1 is located in the inner mitochondrial membrane, where it maintains mitochondrial membrane potential and inhibits apoptosis. In HAX1 deficiency, loss of mitochondrial membrane potential and increased cytochrome c release promote apoptosis of myeloid progenitor cells.
Normally, G-CSF (CSF3) binds to CSF3R and activates signaling pathways such as STAT3 and MAPK to promote neutrophil production. In congenital agranulocytosis, this process is impaired, reducing the response to G-CSF, and acquisition of acquired CSF3R mutations during long-term G-CSF treatment is the basis for leukemic transformation.
Recurrent bacterial infections occur from the first weeks to months of life. Major manifestations include omphalitis, skin infections (pyoderma, cellulitis, folliculitis), pneumonia, pleuritis, liver abscess, splenic abscess, otitis media, sinusitis, and life-threatening sepsis (bacteremia).
Because of neutrophil deficiency, local inflammatory responses to bacterial infection (pus, abscess) may not form sufficiently, so 'infection without fever' can occur. Common pathogens: Staphylococcus aureus, gram-negative bacteria (Pseudomonas aeruginosa, Escherichia coli, Klebsiella).
Gingivitis, recurrent oral ulcers, and early tooth loss are characteristic, resulting from chronic bacterial infection in the oral cavity due to neutrophil deficiency.
HAX1 mutations affecting isoform B may be accompanied by neurological symptoms such as seizures, developmental delay, and cognitive impairment.
Fever and local signs of inflammation depending on the site of infection, gingivitis, oral ulcers. Splenomegaly (response to chronic infection). Hepatomegaly (liver abscess or response to infection). Evidence of skin infections (recurrent cellulitis, scars).
| Test item | Result |
|---|---|
| Absolute neutrophil count (ANC) | <500/μL (definition of severe SCN), <200/μL in agranulocytosis |
| White blood cell differential | Absent or extremely reduced neutrophils; compensatory increase in monocytes and eosinophils possible |
| Hemoglobin, platelets | Initially normal; anemia may accompany chronic infection |
Bone marrow examination characteristically shows maturation arrest at the promyelocyte or myelocyte stage. Mature neutrophils (band and segmented neutrophils) are markedly reduced or absent. Morphological abnormalities (vacuolization, abnormal nuclei) may be observed in progenitor cells.
Congenital neutropenia is suspected in infants with recurrent and severe bacterial infections within the first few months of life, or in children with an absolute neutrophil count <500/μL on CBC.
Complete blood count (CBC) + 5-part white blood cell differential: confirm neutropenia. Repeat CBCs (at least 3 times, 3 weeks apart) are performed to distinguish from cyclic neutropenia. Confirmation of persistent ANC <500/μL on CBC is key.
Bacterial cultures (blood, urine, skin lesions), chest X-ray, and abdominal ultrasound are performed to determine the site and extent of current infection.
To establish the diagnosis, bone marrow aspiration and biopsy are performed to assess the stage of neutrophil maturation arrest and morphological features. Cellularity, distribution of each lineage, and maturation stages are analyzed.
A congenital neutropenia NGS panel including the main causative genes such as ELANE, HAX1, G6PC3, and GFI1 is performed. If no causative variant is identified, whole-exome or whole-genome sequencing is additionally considered.
In patients receiving G-CSF treatment, regular monitoring for acquired CSF3R mutations (truncating mutations) and RAS mutations is performed for early detection of transformation to MDS/AML.
G-CSF (filgrastim) is the first-line treatment for congenital agranulocytosis. Initial dose: 3–5 μg/kg/day subcutaneously, maintaining a target ANC >1,000/μL. The dose is adjusted individually, and some patients require high doses (>30 μg/kg/day). G-CSF treatment has markedly reduced infection frequency and hospitalization rates.
For acute infections, intravenous broad-spectrum antibiotics (covering anti-staphylococcal and gram-negative organisms). Prophylactic antibiotics (trimethoprim-sulfamethoxazole, in some cases) may be used to prevent recurrent infections.
HSCT is indicated in the following cases.
Allogeneic HSCT is performed from an HLA-matched sibling donor (MSD) or matched unrelated donor (MUD). After successful HSCT, neutrophil function is restored.
Oral hygiene care (prevention of inflammation), regular dental checkups, vaccination (inactivated vaccines preferred), and nutritional support are provided concurrently.
Before G-CSF treatment, infant mortality from severe infections was very high. After the introduction of G-CSF treatment, most patients came to survive into adulthood, and quality of life also improved markedly.
The cumulative risk of transformation to MDS or AML during long-term G-CSF treatment is reported to be about 10–15% at 10 years and about 20–25% at 20 years. Acquisition of acquired CSF3R mutations is the main risk factor for leukemic transformation.
With successful HSCT from an HLA-matched donor, long-term survival reaches about 80–90%. After HSCT, patients are freed from G-CSF dependence and the risk of leukemic transformation also decreases.
Maintaining ANC at an adequate level with continuous G-CSF treatment is the most effective measure for preventing infection. Prophylactic antibiotics (TMP-SMX) are used in some cases. Vaccinations (influenza, pneumococcal, meningococcal, varicella) are thoroughly administered. Dental infections are prevented by maintaining oral hygiene.
Genetic counseling is provided to parents for AR inheritance (HAX1, G6PC3, etc.). Prenatal genetic testing (CVS, amniocentesis) or PGT-M is possible.
In patients receiving G-CSF treatment, bone marrow examination and monitoring for CSF3R and RAS mutations 1–2 times a year are recommended. If an abnormal clone is detected, HSCT should be considered early.